Datavant

1.1 Identity and platform

Datavant describes its mission as making health data secure, accessible, and actionable, and its product surfaces position the company as infrastructure for moving, protecting, connecting, and activating patient-level data. The product scope spans privacy-preserving tokenization, data linkage, medical-record retrieval, real-world evidence, and workflow support for providers, payers, life sciences, legal and insurance organizations, and government users. An independent profile similarly describes a healthcare data collaboration platform, while a third-party product profile describes deployment through on-premise, command-line, desktop, or cloud environments. This is a broad platform identity rather than a single-application software profile, and the mix of technology and value-added services should be diligence-tested.[CO001, CO002, CO003, CO004]

1.2 Scale and commercial footprint

The retained materials support a meaningful operating footprint, but the figures are company or partner descriptions rather than audited financial disclosures. Datavant says its network includes more than 80,000 hospitals and clinics, more than 75% of the largest 100 health systems, 100% of U.S. payers, and 350-plus real-world data partners; a 2026 release also says more than 60 million records move between thousands of organizations. A company page states that 1,500 terabytes are exchanged and one trillion records are tokenized annually. These are indicators of network reach and activity, not revenue, ARR, margin, customer retention, or cash generation. The public record therefore supports scale as an operating thesis while leaving monetization and concentration unverified.[CO005, CO006, CO007, CO008, CO009]

1.3 Leadership, partnerships, and key-person dependence

The retained sources identify operating leaders in product and growth roles and document a multi-year partner relationship, but they do not provide a complete founder, executive, board, or ownership roster. Andrea Kowalski is identified as Senior Vice President of Provider Products and Steve Mallinak as Chief Growth Officer for Provider in the 2026 Provider Exchange announcement; Tal Rosenberg is identified as President and GM for Life Sciences, Ecosystem and Public Sector in the 2024 Premier release. Premier says its collaboration with Datavant began in September 2022, and the parties expanded it in 2024 around trial tokenization and real-world evidence. This supports functional coverage and ecosystem execution, while leaving key-person dependency and governance diligence open.[CO010, CO011, CO012, CO013]

1.4 Milestones and evidence gaps

The milestone record shows a progression from trial-tokenization activity to broader ecosystem and provider workflow products. Premier's release says Datavant launched its trial-tokenization offering in 2019 and had tokenized more than 100 clinical trials by February 2024. The same release documents the September 2022 start of the PAS collaboration, while the 2026 Provider Exchange announcement marks a current expansion into provider-driven retrieval. The evidence does not establish founding date, original founders, financing chronology, current valuation, debt, revenue, headcount, or the economics of any sponsor-backed ownership. A diligence process should obtain cap-table and financing documents, current management and board materials, product-line revenue and margin data, and customer concentration metrics before underwriting.[CO014, CO015, CO016]

1.5 Exhibits

2.1 Market boundary and status quo

Datavant's addressable opportunity is best bounded as the infrastructure and services used to acquire, retrieve, connect, protect, and operationalize healthcare data for providers, payers, life-sciences companies, analytics firms, and public-sector users. This excludes the much larger value of care delivery, drug sales, hospital software generally, and raw data ownership unless Datavant is paid to move, link, govern, or make those data usable. The status quo is not one competitor: it includes fax, email, phone follow-up, manual release-of-information labor, point-to-point health information exchange, internal EHR workflows, and buying or building separate data assets. MedCity News reports that providers still often use fax, email, phone calls, and manual follow-ups, while Datavant's own data-logistics paper describes healthcare data as siloed across thousands of sites and databases. The market therefore has a workflow-efficiency wedge as well as a data-network and privacy-infrastructure wedge. Adoption is likely to begin where missing or delayed records have an immediate operational or research cost, then expand into recurring connectivity and analytics workflows.[CM001, CM002, CM003, CM004]

2.2 Evidence-constrained sizing

Public evidence supports several non-equivalent sizing lenses, but it does not support adding them together. Datavant's authored paper cites a global healthcare data analytics market of $21.1 billion in 2021 reaching $85.9 billion by 2027, a global interoperability market expected to approach $16 billion by 2030, and a global enterprise data-management market growing from $77.9 billion in 2020 to $122.9 billion by 2025. These are adjacent categories with different publishers, geographies, definitions, and periods; they are not a Datavant TAM. The same paper reports that patient-level records per patient rose from about 59 in 2019 to 86 in 2023 and that provider NPIs increased 66% from 2019 to 2023, which supports demand growth but not revenue capture. Partner and product evidence points to narrower monetizable wedges: clinical-trial linkage, payer/provider clinical insights, health-plan retrieval and chart research, and provider record exchange. A defensible SAM/SOM still requires Datavant's current revenue by product, contract sizes, renewal rates, eligible account universe, and the portion of delivery that is software versus services.[CM005, CM006, CM007, CM008, CM009]

2.3 Buyer segments, drivers, and constraints

Buyer ownership follows the workflow being solved. Providers and health systems can own budgets for retrieval, release-of-information, and care-coordination workflows; payers and risk-bearing providers can own budgets for chart acquisition, risk adjustment, quality, and member management; life-sciences companies and contract research organizations can own budgets for real-world evidence, trial recruitment, and longitudinal patient-data linkage; analytics and data partners can fund connectivity and privacy infrastructure. The strongest adoption triggers are measurable administrative burden, time-sensitive records, regulatory or audit requirements, and a need to combine datasets without exposing patient identity. MedCity News describes an early tissue-and-organ-donation customer with only a day or two to review a donor's history, while Premier describes real-world evidence control-arm and trial-linkage use cases. Constraints remain material: privacy and de-identification obligations, heterogeneous source systems, dependence on the counterparty's response time, integration and change-management effort, and unclear public pricing. Datavant's reported rollout of less than a week for early Provider Exchange users is encouraging, but it is a company executive's statement and should not be generalized to all products or customers.[CM010, CM011, CM012, CM013, CM014]

2.4 What remains unproven

The evidence supports a credible market need and several distribution wedges, but not a clean investment-grade market share calculation. Company and partner materials provide network and workflow metrics, while independent coverage provides operating examples; none discloses current Datavant revenue, recurring revenue, product-level gross margin, pricing, win rates, or the denominator needed to convert network scale into wallet share. Public category estimates also mix global and U.S. markets and combine software, services, data, and infrastructure. The central diligence task is therefore to reconcile product-level bookings or revenue with the eligible buyer universe and to separate pass-through data or services revenue from software-like recurring revenue. A buyer reference set should test whether the value proposition is budgeted as interoperability, release-of-information labor, analytics, compliance, or research spend, because those budget owners imply different sales cycles and competitive sets.[CM008, CM009, CM013, CM014]

2.5 Exhibits

3.1 Competitive landscape and buyer alternatives

The relevant competitive set is a job-to-be-done landscape, not a list of products with identical scope. Datavant's documented offer spans record retrieval and exchange, tokenization, patient-level linkage, privacy services, and real-world data connectivity. That places it alongside health-information exchange and interoperability infrastructure, specialist identity-resolution or tokenization vendors, real-world-data marketplaces, and outsourced release-of-information and abstraction providers. Buyers can also use an incumbent EHR or data-exchange stack, contract directly with data partners, build internal matching and governance workflows, or run a manual status quo. The independent dossier cautions that a capability label does not establish package depth, configuration, implementation effort, or legal fitness, so category overlap should not be treated as product equivalence.[CP001, CP002, CP003]

3.2 Capability, distribution, and trust comparison

Datavant's strongest disclosed comparison points are ecosystem breadth, privacy-preserving linkage, and the combination of software with value-added data operations. A partner announcement describes Datavant Connect as supporting tokenization, data-partner discovery, and individual-level dataset connection while preserving patient privacy; the same announcement reports Datavant's statement that it had tokenized more than 100 clinical trials. Datavant's own materials describe a network spanning providers, payers, life sciences, government, and other stakeholders, and identify controls for privacy, consent, de-identification, and expert governance. These are positioning and partnership claims, not independent benchmark results. For alternatives, public evidence in the assigned pool is insufficient to populate feature-by-feature cells, pricing, match accuracy, uptime, or implementation effort without guessing.[CP004, CP005, CP006, CP007]

3.3 Switching costs, lock-in, and moat durability

Potential durability comes from the accumulated network of data partners, provider access, tokenization relationships, compliance workflows, and domain operations needed to connect records across organizations. The partner evidence reports access to more than 70,000 hospitals and clinics, 70 percent of the 100 largest health systems, and 500-plus real-world data partners in the 2024 release; current official materials present different scale figures, including 80,000-plus hospitals and clinics, 350-plus real-world data partners, and one trillion records tokenized annually. The difference demonstrates that network metrics are time- and definition-sensitive, not a verified growth series. Customers may still multi-home across data exchanges, retain their own data and matching processes, or substitute direct integrations and services. The assigned evidence does not quantify churn, contract duration, migration cost, exclusive access, or competitor win rates.[CP008, CP009, CP010, CP011]

3.4 Pricing, displacement risk, and diligence priorities

Public pricing is not established in this pool. A software directory explicitly directs prospective buyers to the official website for current pricing and plans, while the independent dossier says package, depth, configuration, and production behavior require verification. The likely buying trade-off is therefore between a broad, managed connectivity and data-operations footprint and more modular point solutions or internal build. Datavant's own interoperability guide acknowledges that healthcare interoperability remains difficult and that standards compete, which supports a continuing need for integration expertise but also leaves room for incumbents, standards-based platforms, and lower-cost automation to narrow the gap. Underwriting should test realized price by workflow, services intensity, implementation duration, customer concentration, multi-homing, and the portability of tokens and linked datasets.[CP012, CP013, CP014]

3.5 Exhibits

4.1 Revenue model and monetization

Datavant's public surfaces describe several monetizable streams rather than a single software subscription: privacy-preserving connectivity and tokenization, data retrieval and release-of-information services, risk-adjustment coding, and value-added real-world-data and analytics workflows. The commercial-pharma page says Datavant supports commercial analytics, HEOR, advertising measurement, patient-support programs, and future drug development, while also describing Smart Request retrieval and annual record volume. That breadth can increase wallet share and embed the platform in regulated workflows, but it also means revenue quality likely varies by product, contract, utilization, and labor content. The public evidence supports a mechanism map, not a revenue mix or accounting conclusion: no assigned source gives current revenue, ARR, realized price, gross margin, renewal, or customer concentration. Official list or capability descriptions should therefore not be treated as realized revenue or unit economics.[CI001, CI002, CI003, CI004]

4.2 Traction and sales-efficiency proxies

Public traction is strongest in network and activity proxies. Datavant states that more than 60 million healthcare records move between thousands of organizations, while its network includes more than 80,000 hospitals and clinics, 350-plus real-world-data partners, and 75% of the 100 largest health systems. Its commercial-pharma page separately describes 40-plus life-science customers, more than 100 brands and trials, more than 40,000 medical facilities, and more than 64 million annual retrievals. A March 2026 company release adds that Datavant exchanged more than 40 million medical records in the prior year and codes more than 30 million records annually. These measures indicate reach and throughput, but they are not interchangeable: records moved, exchanged, retrieved, and coded have different scopes and periods, as do partner, facility, customer, brand, and trial counts. No source reports sales cycle, CAC, payback, bookings, win rate, or channel take rate. The diligence priority is cohort-level conversion from activity into contracted recurring or transaction revenue.[CI005, CI006, CI007, CI008]

4.3 Cost structure and capital adequacy

The operating model appears to combine technology with substantial data operations and services. Datavant describes record retrieval, coding, privacy expertise, data preparation, and expert-governed deployment alongside connectivity infrastructure. Premier's partner announcement says the platform links trial and real-world data, while the commercial-pharma page calls Datavant the largest record-retrieval company in the United States and reports more than 64 million annual retrievals. That mix can create variable delivery costs, labor exposure, quality-control expense, and working-capital needs that are not visible in a software-style margin assumption. The assigned evidence does not report cash on hand, debt, covenant terms, burn, runway, capex, acquisition consideration, or post-acquisition integration cost. The 2021 Ciox transaction announcement records a $7.0 billion transaction value and more than $700 million of revenue for the combined company at that historical point, but neither figure is current and neither establishes cash available today.[CI009, CI010, CI011, CI012]

4.4 Financial verdict and diligence blockers

Datavant has credible evidence of scale, partner adoption, and multiple monetization surfaces, but public disclosure is insufficient for underwriting a current valuation or margin path. The strongest positive case is that connectivity, retrieval, coding, privacy, and data-activation services may reinforce one another and create workflow switching costs. The principal adverse case is that acquisition-led expansion and operational complexity can obscure organic growth and dilute margins; the assigned Built In page explicitly flags limited financial transparency, acquisition dependence, integration complexity, and inconsistent revenue figures. This source is an AI-generated company profile and is not a substitute for audited financial statements, but it is a useful adverse signal about the disclosure gap. A financing decision should remain conditional on product-level revenue and gross-margin bridges, cohort retention, customer concentration, cash and debt schedules, burn/runway, and evidence separating software from labor-heavy services.[CI013, CI014, CI015, CI016]

4.5 Exhibits

5.1 Product workflow and customer job

Datavant's product is best understood as infrastructure for moving and combining health data rather than as a single clinical application. The documented workflow starts with tokenizing data, then assessing metadata and overlap, connecting records at the patient level, applying privacy or expert-determination processes, and distributing data to authorized recipients. The AWS datasheet describes on-premise or cloud tokenization, comparison of dataset overlap without exchanging data, patient-level matching, and delivery of custom segments. This maps to a customer job of making fragmented data usable across a research, care, payer, or life-sciences workflow while retaining control over access. The public material is strongest on workflow stages and intended use; it does not establish service-level objectives, implementation times, or realized customer economics.[CE001, CE002, CE003, CE004]

5.2 Architecture, deployment, and integration surface

The available technical description indicates a distributed connectivity architecture with site-specific irreversible tokens, matching and referential data, partner discovery, project and workflow management, and controlled permissions. Datavant Connect is described as deployable through a command-line interface, desktop UI, or a customer's cloud environment, while the AWS material describes native tokenization on AWS, de-identified datasets in Amazon S3, and a workflow using AWS Clean Rooms. These are concrete deployment and integration surfaces rather than proof of a single standardized stack. A separate partner account describes integration of Datavant technology into Thermo Fisher's PPD business, CorEvitas registries, and Evidera solutions. The evidence supports interoperability as a product design goal, but leaves open the exact APIs, supported cloud configurations, data residency model, observability, and customer-controlled rollback procedures.[CE005, CE006, CE007, CE008]

5.3 Maturity, use cases, and delivery model

Public evidence spans mature connectivity use cases and newer AI-enabled workflow claims. The Premier release says the parties had worked together since September 2022, that Datavant had tokenized more than 100 clinical trials by February 2024, and that linked trial and real-world data were being used for patient journeys, real-world control arms, candidate identification, and site identification. The 2026 Datavant AI article describes a more developmental agentic platform operating across Datavant Connect and Aetion Evidence, with stepwise deployment, retrieval-augmented contexts, scientific evaluations, and human review points. A current job posting also describes pre-sales solutioning across commercial analytics, market access, patient services, and evidence use cases. Together these sources suggest a platform-plus-services operating model with broad use-case reach, but do not independently verify adoption, production scale, or repeatability across customers.[CE009, CE010, CE011, CE012]

5.4 Trust, safety, and implementation risks

Datavant's public surface emphasizes privacy, security, compliance, and governed use: the company describes privacy and security by design, threat modeling, and phish-resistant MFA, while its AI article describes human-supervised workflows, scientific evaluations, auditability, and production thresholds. Partner and company materials also describe HIPAA-oriented de-identification and controlled access. These statements establish the intended control framework, not independent certification scope, breach resilience, false-match rates in production, or the legal sufficiency of every use case. A historical partner release provides concrete implementation examples but is company/partner-issued, and the technical marketplace datasheet is also not an independent benchmark. Diligence should therefore test controls and outcomes directly, including independent SOC 2 or regulatory artifacts, token rotation and reversibility controls, match-quality by cohort, incident history, change management, and the labor required to configure and review workflows.[CE013, CE014, CE015, CE016]

5.5 Exhibits

6.1 Customer segments and buying jobs

Datavant addresses a multi-sided healthcare-data market rather than a single buyer profile. Its official pages identify providers, health plans, life sciences, data analytics, and public-sector organizations, while partner evidence adds data suppliers and clinical-research teams. The common buying job is secure movement, linkage, retrieval, or evaluation of patient-level data, but the user and payer can differ: a provider may operate release-of-information workflows, a health plan may consume clinical data, and a life-sciences team may buy access to linked datasets. Rx Almanac characterizes the commercial motion as custom and RFP-led, with scope depending on volumes, modules, and partner mix. That breadth supports several monetization surfaces, but public segment labels do not disclose customer counts, revenue mix, average contract value, or geographic concentration.[CU001, CU012, CU013]

6.2 Scale signals and adoption trajectory

Datavant's current public materials report more than 80,000 hospitals and clinics, coverage of all U.S. health plans directly or through health-system customers, 350-plus real-world-data partners, and relationships with all 20 top pharmaceutical companies. These measures show network breadth across both supply and demand, and a third-party product listing repeats the 350-partner and top-pharma claims. They are not comparable customer metrics: provider sites, payer coverage, ecosystem partners, and corporate relationships use different denominators and may include non-paying or indirectly reached organizations. Premier's February 2024 announcement supplies a dated operating marker by quoting Datavant as having tokenized more than 100 clinical trials, but neither source set publishes an active-account series, utilization cohort, or revenue conversion rate.[CU002, CU003, CU004, CU005, CU010]

6.3 Named deployments and outcome quality

The assigned evidence includes three concrete operating contexts. Veradigm described itself as an early adopter of Datavant Connect and said its clinical registries would become available for faster discovery and evaluation by life-sciences teams. Premier said its collaboration with Datavant had operated since September 2022 and described an active chronic-condition trial linking trial data with Premier Healthcare Data. Datavant's Florida Woman Care case study describes centralized intake and automated EHR retrieval, with higher digital fulfillment in 2025. These examples go beyond logo display because they identify workflows and users, yet evidence quality remains mixed: two accounts are partner-issued, one is company-issued, customer identities are sometimes withheld, and the sources omit measured purchase conversion, baseline fulfillment rates, contract value, and renewal history.[CU006, CU007, CU008, CU009, CU011, CU014]

6.4 Durability, expansion, and concentration

The evidence supports a plausible expansion mechanism but not measured expansion economics. A data provider can connect inventory and gain discoverability; a life-sciences buyer can evaluate data and deploy linkage in a trial; a provider can automate record retrieval; and adjacent datasets or workflows can then be added. This sequence could increase embeddedness, but it is an analytical synthesis rather than a reported customer journey or conversion funnel. No assigned source discloses NRR, GRR, logo churn, renewal rates, contract length, top-customer revenue share, or partner and channel concentration. Those omissions are material because a large network may coexist with shallow usage, services-heavy delivery, or concentrated revenue. Underwriting should therefore rely on private cohort, contract, utilization, and concentration data rather than interpreting reach metrics as proof of durability.[CU007, CU012, CU013, CU014, CU015]

6.5 Exhibits

7.1 Risk posture and highest-consequence exposures

Datavant operates in a high-consequence environment because its products connect, retrieve, and tokenize patient-level health information. The operating model therefore creates a compound risk surface: a security or privacy failure can create legal exposure, remediation cost, customer trust loss, and regulatory scrutiny at the same time. The strongest adverse evidence in the assigned pool is the reported settlement involving Ciox Health, doing business as Datavant Group, after an email-account compromise that affected 320,702 individuals according to the HHS Office for Civil Rights breach portal. The reported $900,000 settlement and preliminary court approval show that exposure can become a direct legal and cash obligation, although the article does not establish the company's current insurance recovery, remediation spend, or residual control maturity. Datavant's own materials describe secure architecture, threat modeling, and phish-resistant MFA, but company statements are not independent validation of operating effectiveness. The investment implication is that trust infrastructure is a core value driver and a thesis-break risk, not merely a compliance feature.[CR001, CR002, CR003, CR004]

7.2 Operational, technology, and financial-model risks

The platform depends on reliable retrieval, tokenization, matching, access control, and delivery across thousands of healthcare organizations with different systems, formats, and technical capabilities. Datavant's product descriptions emphasize encrypted, site-specific tokens, privacy assessments, and broad network coverage, while its record retrieval materials claim 60M+ records retrieved annually, 80%+ yield, and access workflows spanning any U.S. facility. These are company-published operating assertions, so the key diligence issue is whether service levels, yield, turnaround, and error rates are contractually measured across customer cohorts rather than presented as aggregate marketing metrics. Fragmented provider systems and the need for authorizations create execution and working-capital risk even if the software layer performs as designed. Public sources in this pool do not disclose current burn, leverage, margin, customer concentration, claims reserves, or the share of delivery that is labor-intensive. Those gaps limit confidence in downside resilience and should be monitored alongside technical reliability.[CR005, CR006, CR007, CR008]

7.3 Partner, dependency, and thesis-break criteria

Datavant's ecosystem position is a strength but also creates dependency risk. The Thermo Fisher collaboration and the Premier Applied Sciences relationship demonstrate how the platform is embedded in larger research and evidence-generation workflows; they also imply reliance on partner data quality, consent processes, commercial execution, and continued demand from life-sciences customers. Premier described a clinical-trial use case in which linked real-world data supports medication history, follow-up, and a real-world evidence control arm, but its release also warns that forward-looking outcomes may differ materially from expectations. Datavant's public materials state that its network includes 350+ real-world data partners and 80,000+ hospitals and clinics, yet the assigned evidence does not identify counterparty concentration, exclusivity, renewal, or economics. A practical monitoring framework should therefore track security incidents, regulatory findings, retrieval yield and SLA misses, partner loss, customer renewal and concentration, and liquidity. A thesis break would be a repeated material incident, loss of required privacy or regulatory status, sustained failure to meet contracted service levels, or evidence that partner and customer concentration makes the model unable to absorb one large relationship loss.[CR009, CR010, CR011, CR012, CR013, CR014, CR015]

7.4 Exhibits

8.1 Investment thesis and anti-thesis

The positive thesis is that Datavant has accumulated a difficult-to-replicate network position in healthcare data logistics. A recent report says Neuberger Berman and KKR agreed to acquire a significant minority stake while New Mountain Capital retained control, and describes reach of more than 80,000 providers, 75 of the top 100 U.S. health systems, and 350-plus ecosystem partners. Datavant's own platform description also reports 1,500 terabytes exchanged and one trillion records tokenized annually, although those are company-reported operating indicators rather than audited financial KPIs. The anti-thesis is equally material: Tracxn ranks Datavant second among 60 active competitors, and the public materials do not establish revenue, gross margin, retention, leverage, purchase price, or the economic split between software and services. A historical data profile reports $83 million of funding and a 2026 private equity event, but its displayed round fields are opaque and internally inconsistent, so it is a diligence lead rather than a valuation anchor. The resulting investment case is scale-positive but price-unknown.[CV001, CV002, CV003, CV004, CV005, CV006, CV007, CV015]

8.2 Financing context and entry discipline

The September 2026 minority investment is evidence of sponsor appetite, not evidence of the price paid or Datavant's post-money valuation. AlphaMaven's account identifies the investors and New Mountain's continuing control but gives no consideration, ownership percentage, preferred-security terms, liquidation preference, debt package, or dilution schedule. Tracxn's profile supplies a potentially useful historical benchmark, but the page labels Datavant a Series B company, reports $83 million of funding, and presents obfuscated-looking round values while also showing a 2026 PE event; these conflicts make the figures unsuitable for a precise multiple. The 2025 Ontellus announcement does provide strategic context for inorganic growth: Datavant agreed to acquire the records-retrieval company, but the release does not state consideration or financing structure Entry discipline should therefore require a current capitalization table, audited or lender-quality financials, the September transaction announcement or data room terms, and acquisition-adjusted cash-flow metrics before underwriting a premium.[CV001, CV004, CV005, CV008, CV009, CV010]

8.3 Scenarios, recommendation, and thesis-break triggers

A scenario framework is more defensible than a point estimate because the public evidence supports operating scale but not the denominator needed for a revenue multiple or discounted-cash-flow model. The bull case assumes the network converts its connectivity, retrieval, privacy, and AI workflow breadth into durable recurring or repeatable service revenue without disproportionate labor intensity; the base case assumes strategic value persists but economics remain opaque; and the bear case assumes multiple compression, acquisition integration drag, or privacy/compliance friction prevents scale from translating into cash generation. Datavant and its partners describe tokenization, linkage, clinical-trial use, and the Ontellus combination, but these are capability and use-case signals rather than proof of customer retention or profitability. The appropriate current recommendation is research-more with medium confidence and high risk: move toward buy only after price, margins, leverage, retention, and preference terms are verified. No target return, hold period, exit multiple, or numerical valuation range is supportable from the assigned public evidence. A thesis break is an adverse financing or operating disclosure showing weak retention, material leverage, substantial integration losses, or privacy/regulatory remediation that materially reduces cash conversion.[CV006, CV007, CV010, CV011, CV012, CV013, CV014, CV016]

8.4 Exit readiness and final diligence asks

Datavant appears institutionally financeable, but it is not publicly underwritable on valuation. The platform has broad reported connectivity, and Premier says its collaboration has been used to link clinical-trial and real-world data, while Datavant says the platform serves healthcare stakeholders across providers, payers, life sciences, government, and legal and insurance workflows. Those references improve the strategic and exit-readiness case, yet they do not answer who pays, how much is recurring, what gross margin is achievable, or how concentrated counterparties are. The next diligence package should request the current cap table and preferred rights, the September 2026 transaction valuation and ownership, monthly recurring or contracted revenue by product, gross margin by software and services, NRR/GRR, top-customer and partner concentration, net debt and liquidity, and post-Ontellus integration KPIs. Until those items are available, valuation stance remains unknown and a premium entry should not be assumed.[CV001, CV006, CV010, CV011, CV012, CV014]

8.5 Exhibits